In vitro metformin anti-neoplastic activity in epithelial ovarian cancer

Gynecologic Oncology

Volumn 110, Issue 2, 2008, Pages 246-250

  Gotlieb, Walter H ^a,b   Saumet, Julio ^a,b   Beauchamp, Marie Claude ^a,b   Gu, Jing ^a,b   Lau, Susie ^a,b   Pollak, Michael N ^b,c   Bruchim, Ilan ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

AMPK; Cisplatin; Metformin; Ovarian cancer; OVCAR; p70S6K; S6K; Translational research

Indexed keywords

ADENYLATE KINASE; CISPLATIN; METFORMIN; S6 KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADENYLATE KINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; METFORMIN; OVARIAN NEOPLASMS; PHOSPHORYLATION; PYRAZOLES; PYRIMIDINES; RIBOSOMAL PROTEIN S6 KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA;

EID: 47249088612     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.04.008     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Silber J.H., Rosenbaum P.R., Polsky D., Ross R.N., Even-Shoshan O., Schwartz J.S., et al. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?. J Clin Oncol 25 (2007) 1169-1175
3. Gotlieb W.H., Bruchim I., Gu J., Shi Y., Camirand A., Blouin M.J., et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 100 (2006) 389-396
4. Lu L., Katsaros D., Wiley A., Rigault de la Longrais I.A., Rish H.A., Puopolo M., et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-∝ expression to disease progression in epithelial ovarian cancer. Clin cancer res 12 4 (2006) 1208-1214
5. Spentzos D., Cannistra S.A., Grall F., Levine D.A., Pillay K., Libermann T.A., et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer 14 (2007) 781-790
6. Augustin L.S., Polesel J., Bosetti C., Kendall C.W., La V.C., Parpinel M., et al. Dietary glycemic index, glycemic load and ovarian cancer risk: a case-control study in Italy. Ann Oncol 14 (2003) 78-84
7. McCarty M.F. Chronic activation of AMP-activated kinase as a strategy for slowing aging. Med Hypotheses 63 (2004) 334-339
8. Anisimov V.N. Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention. Exp Gerontol 38 (2003) 1041-1049
9. Kahn B.B., Alquier T., Carling D., and Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1 (2005) 15-25
10. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005) 1642-1646
11. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., and Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66 (2006) 10269-10273
12. Li J., Jiang P., Robinson M., Lawrence T.S., and Sun Y. AMPK-beta1 subunit is a p53- independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis 24 (2003) 827-834
13. Bolster D.R., Crozier S.J., Kimball S.R., and Jefferson L.S. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 277 (2002) 23977-23980
14. Wullschleger S., Loewith R., and Hall M. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
15. Yu Y., and Sato J.D. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 178 (1999) 235-246
16. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
17. Holland E.C., Sonenberg N., Pandolfi P.P., and Thomas G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23 (2004) 3138-3144
18. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
19. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., and Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330 (2005) 1304-1305
20. Bowker S.L., Majumdar S.R., Veugelers P., and Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29 (2006) 254-258
21. Emerling B.M., Viollet B., Tomos K.V., and Chandel N.S. Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. Febs Letter 581 (2007) 5727-5731
22. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res 174 (2007) 49-53
23. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179-183
24. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
25. Bailey C.J., and Turner R.C. Metformin. N Engl J Med 334 (1998) 574-579
26. Nestler J.E., Jakubowicz D.J., Evans W.S., and Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338 (1998) 1876-1880 6-25-
27. Holland W., Morrison T., Chang Y., Wiernsperger N., and Stith B.J. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol 67 (2004) 2081-2091
28. Stith B.J., Goalstone M.L., Espinoza R., Mossel C., Roberts D., and Wiernsperger N. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinology 137 (1996) 2990-2999
29. Zou M.H., Kirkpatrick S.S., Davis B.J., Nelson J.S., Wiles IV W.G., Schlattner U., et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 279 (2004) 43940-43951
30. Alexandrov V.A., Anisimov V.N., Belous N.M., Vasilyeva I.A., and Mazon V.B. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats. Carcinogenesis 1 (1980) 975-978
31. Anisimov V.N., Egormin P.A., Bershtein L.M., Zabezhinskii M.A., Piskunova T.S., Popovich I.G., et al. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 139 (2005) 721-723